Lantz Financial LLC Boosts Stake in Sanofi (NASDAQ:SNY)

Lantz Financial LLC increased its stake in shares of Sanofi (NASDAQ:SNY) by 6.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,277 shares of the company’s stock after buying an additional 520 shares during the quarter. Lantz Financial LLC’s holdings in Sanofi were worth $399,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Jennison Associates LLC lifted its stake in Sanofi by 938.0% during the 3rd quarter. Jennison Associates LLC now owns 1,904,445 shares of the company’s stock valued at $109,753,000 after acquiring an additional 1,720,972 shares during the period. Thrivent Financial for Lutherans lifted its position in Sanofi by 28,890.2% during the third quarter. Thrivent Financial for Lutherans now owns 1,429,219 shares of the company’s stock valued at $82,366,000 after purchasing an additional 1,424,289 shares during the period. JPMorgan Chase & Co. boosted its holdings in Sanofi by 20.9% in the third quarter. JPMorgan Chase & Co. now owns 2,310,809 shares of the company’s stock valued at $133,172,000 after purchasing an additional 399,301 shares during the last quarter. Franklin Resources Inc. grew its position in Sanofi by 13.1% during the 3rd quarter. Franklin Resources Inc. now owns 3,407,452 shares of the company’s stock worth $208,106,000 after purchasing an additional 395,744 shares during the period. Finally, Barclays PLC grew its position in Sanofi by 107.5% during the 3rd quarter. Barclays PLC now owns 639,772 shares of the company’s stock worth $36,869,000 after purchasing an additional 331,445 shares during the period. 14.04% of the stock is owned by institutional investors and hedge funds.

Sanofi Price Performance

NASDAQ:SNY opened at $52.48 on Friday. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65. The company has a 50 day moving average price of $48.70 and a 200-day moving average price of $52.17. Sanofi has a 1-year low of $45.22 and a 1-year high of $58.97. The firm has a market cap of $133.19 billion, a price-to-earnings ratio of 26.78, a price-to-earnings-growth ratio of 1.19 and a beta of 0.57.

Sanofi (NASDAQ:SNY) last released its quarterly earnings data on Friday, October 25th. The company reported $1.57 earnings per share for the quarter, beating analysts’ consensus estimates of $0.22 by $1.35. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The company had revenue of $13.44 billion during the quarter, compared to analysts’ expectations of $16.59 billion. During the same quarter in the previous year, the company earned $2.55 earnings per share. The firm’s revenue for the quarter was up 12.3% on a year-over-year basis. Equities research analysts forecast that Sanofi will post 3.82 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, StockNews.com downgraded Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.